The production shortfall for cell therapies and viral vectors could have a devastating effect on the growth and success of the industry but...

Cenk Sumen, Director at Thermo Fisher discuss durability of anticancer therapies and its importance in relation to pricing and reimbursement...

As we see more cell and gene therapies gaining market authorisation, attention is turning to the bioprocesses used for their manufacture,...

Episode three in the top tips series is with Ohad Karnieli, CEO and Co-founder of ATVIO Biotechnology. Ohad gives his unequivocal views on the...

The Automation SIG is a platform to debate, collaborate and work towards genuine solutions for the new paradigm of manufacturing needed...

The small biotech's guide to identifying, setting up and successfully managing partnerships with Susan Nichols, CEO Falcon Therapeutics

The first episode in Phacilitate:Exchange's Top Tips series is brought to you by Lee Buckler, President and CEO of RepliCel Life Sciences...

This collaborative panel, filmed at Phacilitate Leaders World 2018 in Miami, reviews the 2017 Automation SIG. Experts from CGTC, Novartis,...

The UK has a rich and diverse range of preclinical research and is setting the foundations for the therapies of the future. The CGT Catapult’s...

This webinar series has been co-organised by Phacilitate and Biotech and Money/LSX

Is automation the cure for the cost of goods pandemic?

Discover the four cornerstones of improving patient response rates. Combination therapies, precision medicine, trial design and regulatory...

Could outcome-based annuity payments, in which cell and gene therapies are paid for over-time as benefits materialise, increase patient access to...

Phacilitate and Biolacuna have produced a cutting-edge report, which includes the results, data and analysis of an industry-wide survey, plus...

The supply chain story concludes with a focus on commercialisation and scale-up